What is Discngine?
Discngine provides a comprehensive suite of SaaS applications and bespoke IT solutions designed to accelerate the discovery of new molecules within the life sciences. Leveraging over two decades of experience, the company offers platforms for critical research informatics tasks, including protein structure analysis and laboratory informatics. Their client base spans global R&D divisions, demonstrating a strong market presence and a deep understanding of the complex challenges faced by the pharmaceutical, cosmetics, and agrosciences sectors. Discngine also offers expert consulting services for the development of custom scientific software, further solidifying its position as a key technology partner in life science innovation.
How much funding has Discngine raised?
Discngine has raised a total of $1.3M across 1 funding round:
Series A
$1.3M
Series A (2017): $1.3M with participation from Extens Du00e9veloppement e-Santu00e9
Key Investors in Discngine
Extens Développement e-Santé
Extens is a French private equity investment fund focused exclusively on healthcare software, investing in high-potential companies within the e-health sector since 2014. They are committed to supporting the growth of their portfolio companies to become industry leaders.
What's next for Discngine?
With the recent major strategic investment, Discngine is poised for accelerated growth and further innovation in its life science informatics solutions. The substantial capital infusion is expected to fuel the expansion of its SaaS offerings and enhance its consulting services, enabling the company to address increasingly complex research and development challenges. This strategic backing will likely support Discngine in deepening its market penetration within the pharmaceutical, cosmetics, and agrosciences industries, potentially leading to new product developments and broader adoption of its advanced molecule discovery tools. The company's focus on R&D informatics positions it to capitalize on the ongoing demand for efficient and effective drug and molecule discovery processes.
See full Discngine company page
